Monday, September 18, 2023
News Health
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

EU Regulator Recommends Stopping Sale of Blood Cancer Drug

September 18, 2023
in Health News
Share on FacebookShare on Twitter


(Reuters) – The EU drug regulator on Friday recommended against renewing the conditional marketing authorisation for GSK’s blood cancer drug Blenrep, which GSK stopped selling in the U.S. last year at the request of the U.S. Food and Drug Administration.

Shares in the British drugmaker were up 1.8% at 1343 GMT. A GSK shareholder told Reuters this was unsurprising given what was already decided in the United States.

But one analyst said that the news was a reminder of GSK’s need to bolster its pipeline of drugs in development, having suffered a series of clinical trial setbacks in its cancer drugs portfolio over the past year.

Only a few years ago, GSK had pushed to rebuild its oncology portfolio, in part through deals such as the $5.1 billion purchase in 2019 of U.S. biopharmaceuticals company Tesaro.

Though the EMA’s decision was expected, “This underscores how the company needs something else to bolster its pipeline,” said UBS analyst Michael Leuchten.

Last November Blenrep failed to meet the main goal in a late-stage study designed to show it was better than an existing treatment on the market, leading GSK to stop selling it in the United States.

GSK will request a re-examination of the decision based on its belief that the risk-benefit profile for the drug remains favourable, a spokesperson said.

But given that the drug had already been pulled from the U.S. market and Blenrep only accounted for 9 million pounds ($11.18 million) of sales in the second quarter of this year, the EU regulator’s decision on Friday was “kind of a non-event”, a second analyst told Reuters.

The blood cancer drug made 118 million pounds in sales in 2022, the second-largest contributor to the company’s oncology business.

Recommendations made by the human medicines committee will have to be formally approved by the European Commission.

($1 = 0.8053 pounds)

(Reporting by Khushi Mandowara in Bengaluru; Editing by Shounak Dasgupta and Louise Heavens)



Source link : https://www.medscape.com/s/viewarticle/996498?src=rss

Author :

Publish date : 2023-09-18 17:16:07

Copyright for syndicated content belongs to the linked Source.
Previous Post

Does Anti-Reflux Surgery Cut Esophageal Cancer Risk?

Related Posts

Health News

Does Anti-Reflux Surgery Cut Esophageal Cancer Risk?

September 18, 2023
Health News

Spinal fluid test may enable earlier diagnosis of Parkinson’s disease

September 18, 2023
Health News

Thankful for the Little Things

September 18, 2023
Health News

Does Adding Ipilimumab to Nivolumab Improve Cancer Outcomes?

September 18, 2023
Health News

Real-World Data Confirm Efficacy of Dupilumab in Severe EoE

September 18, 2023
Health News

Surge in Peds ADHD Med Errors Prompts Call for Prevention

September 18, 2023
Load More

EU Regulator Recommends Stopping Sale of Blood Cancer Drug

September 18, 2023

Does Anti-Reflux Surgery Cut Esophageal Cancer Risk?

September 18, 2023

Spinal fluid test may enable earlier diagnosis of Parkinson’s disease

September 18, 2023

Thankful for the Little Things

September 18, 2023

Does Adding Ipilimumab to Nivolumab Improve Cancer Outcomes?

September 18, 2023

Real-World Data Confirm Efficacy of Dupilumab in Severe EoE

September 18, 2023

Surge in Peds ADHD Med Errors Prompts Call for Prevention

September 18, 2023

Islet+Kidney Transplants Boost Survival in Type 1 Diabetes

September 18, 2023
Load More

Categories

Tags

curcumin (2) diet (2) Keto (2)

Archives

September 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
« Aug    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version

EU Regulator Recommends Stopping Sale of Blood Cancer Drug- https://www.matt-daly.com   https://www.instruments-demusique.com/   https://www.1001vins.info/   https://newshealth.biz   https://monmaillotdebain.com   https://www.news-in-europa.com   https://chaussuresx.fr   https://signaturecleaningtn.com   -/- GCHQ breached privacy rights of IT professional and security researcher, human rights court rules   Klischtschijiwka: Ukrainische Armee meldet Rückeroberung weiteren Dorfes nahe Bachmut   Mini Chitarra Da Collezione Replica in Legno-Black Label Society-Zakk Wylde [Import]   -*- Yes beats U Mobile’s 5G unlimited home broadband with better and cheaper subscription   ECB pledge to treble number of girls teams by 2026   */* Hen And Stag Accessories Lot De 4 Saxophones Gonflables   X24 BOUTEILLES Château Beaucastel « Hommage à Jacques Perrin » 2014 75 cl AOC Châteauneuf du Pape Vin Rouge   Bach au XXIe Siècle : Bach et ses Fils (+ 1 CD)   * A.J. Ellender football game postponed following severe weather on Thursday night   A Treblinka, les chambres à gaz du camp d’extermination sortent de terre   EU Regulator Recommends Stopping Sale of Blood Cancer Drug *EU Regulator Recommends Stopping Sale of Blood Cancer Drug

NEWSHEALTH : EU Regulator Recommends Stopping Sale of Blood Cancer Drug